EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic

Vincenzo Di Stefano iD, Antonino Lupica, Paolo Alonge, Antonia Pignolo, Sofia Maria Augello, Francesca Gentile, Andrea Gagliardo, Francesca Giglia, Daniele Brinch, Maria Cappello, Daniela Di Lisi, Giuseppina Novo und 3 weitere

European Journal of Neurology · 2024-01 · 31 (1)

DOI: 10.1111/ene.16065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 19.09.2023. Verfasst von Vincenzo Di Stefano und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Neurology, Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Polyneuropathies. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alnylam Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PN) is caused by mutations in the TTR gene, leading to misfolded monomers that aggregate generating amyloid fibrils.

Methods

A prospective systematic genetic screening for ATTRv‐PN was proposed in patients presenting with a sensory–motor idiopathic polyneuropathy and two or more “red flags” among the following: family history of polyneuropathy or cardiopathy, bilateral carpal tunnel syndrome, cardiac insufficiency, renal amyloidosis, lumbar tract stenosis, autonomic dysfunction, idiopathic gastrointestinal disease, amyloid deposits on biopsy, and vitreous opacities. The detection rate was calculated, and nonparametric analyses were carried out to underline differences among screened positive versus negative patients.

Results

In the first step, 145 suspected patients underwent genetic testing, revealing a diagnosis of ATTRv‐PN in 14 patients (10%). Then, cascade screening allowed early recognition of 33 additional individuals (seven symptomatic ATTRv‐PN patients and 26 presymptomatic carriers) among 84 first‐degree relatives. Patients with a positive genetic test presented a higher frequency of unexplained weight loss, gastrointestinal symptoms, and family history of cardiopathy.

Conclusions

A systematic screening for ATTRv‐PN yielded an increased recognition of the disease in our neurological clinic. Unexplained weight loss associated with axonal polyneuropathy had the highest predictive value in the guidance of clinical suspicion. A focused approach for the screening of ATTRv‐PN could lead to an earlier diagnosis and identification of asymptomatic carriers, who will be promptly treated after a strict follow‐up at the clinical onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialPolyneuropathiesHumansProspective StudiesSicilyGenetic TestingWeight Loss

Stichwörter der Autor:innen

amyloidgeneticsneuromuscularneuropathyneurophysiology

Autor:innen und Institutionen

  • Section of Neurology, Department of Biomedicine, Neuroscience, and Advanced Diagnostics, University of Palermo, Palermo, Italy.
  • Unit of Neurology With Stroke Unit, S. Giovanni di Dio Hospital, Agrigento, Italy.
  • Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties, University of Palermo, Palermo, Italy.
  • Section of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties, University of Palermo, Palermo, Italy.
  • Unit of Neuromuscular Diseases, Oasi Research Institute, IRCCS, Troina, Italy.

ORCID-Profile: Vincenzo Di Stefano

Förderung

  • Alnylam Pharmaceuticals

Zitieren

APA

Di Stefano, V., Lupica, A., Alonge, P., Pignolo, A., Augello, S. M., Gentile, F., Gagliardo, A., Giglia, F., Brinch, D., Cappello, M., Di Lisi, D., Novo, G., Borgione, E., Scuderi, C., & Brighina, F. (2024). Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic. European Journal of Neurology, 31(1). https://doi.org/10.1111/ene.16065

Vancouver

Di Stefano V, Lupica A, Alonge P, Pignolo A, Augello SM, Gentile F, et al. Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic. European Journal of Neurology. 2024;31(1). doi:10.1111/ene.16065

BibTeX
@article{DiStefano2024,
  author = {Di Stefano, Vincenzo and Lupica, Antonino and Alonge, Paolo and Pignolo, Antonia and Augello, Sofia Maria and Gentile, Francesca and Gagliardo, Andrea and Giglia, Francesca and Brinch, Daniele and Cappello, Maria and Di Lisi, Daniela and Novo, Giuseppina and Borgione, Eugenia and Scuderi, Carmela and Brighina, Filippo},
  title = {Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {1},
  doi = {10.1111/ene.16065}
}
Kostenlos starten →